Characteristics and outcome of chronic myeloid leukemia patients with F317l BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

Elias Jabbour, Hagop M. Kantarjian, Dan Jones, Neeli Reddy, Susan O'Brien, Guillermo Garcia-Manero, Jan Burger, Jorge Cortes

Research output: Contribution to journal › Article › peer-review

69 Scopus citations

Fingerprint

Dive into the research topics of 'Characteristics and outcome of chronic myeloid leukemia patients with F317l BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds